Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis

Patricia Barrionuevo, Mohammed Nabhan, Osama Altayar, Zhen Wang, Patricia J. Erwin, Noor Asi, Kathryn A. Martin, Mohammad H Murad

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background Several pharmacologic treatments for hirsutism are used in practice; however, their relative efficacy is unclear. Methods We searched MEDLINE, EMBASE, and CENTRAL through January 2017 for randomized controlled trials (RCTs) with follow-up of at least 6 months that evaluated antiandrogens, insulin sensitizers, and oral contraceptives in women with hirsutism. Independent pairs of reviewers selected and appraised trials. Random-effects network meta-analysis was used to compare individual drugs and classes. Results We included 43 trials. Estrogen-progestin oral contraceptives pills (OCPs), antiandrogens, and insulin sensitizers were superior to placebo, with standardized mean reductions (95% confidence intervals) of -0.94 (-1.49 to -0.38), -1.29 (-1.80 to -0.79), and -0.62 (-1.00 to -0.23), respectively. Antiandrogen monotherapy, the combination of OCP and antiandrogen, the combination of OCPs and insulin sensitizer, and the combination of antiandrogen and insulin sensitizer were superior to insulin sensitizer monotherapy. The combination of OCPs and antiandrogen was superior to OCPs. Antiandrogen monotherapy with flutamide, finasteride, and spironolactone were each superior to placebo but similar to each other in efficacy. OCPs containing levonorgestrel, cyproterone acetate, or drospirenone were similar in effectiveness to other OCPs or had trivial differences. The certainty in comparisons with placebo was moderate and for head-to-head comparisons was low. Conclusions Estrogen-progestin OCPs, antiandrogens, and insulin sensitizers are superior to placebo for the treatment of hirsutism.

Original languageEnglish (US)
Pages (from-to)1258-1264
Number of pages7
JournalJournal of Clinical Endocrinology and Metabolism
Volume103
Issue number4
DOIs
StatePublished - Apr 1 2018

Fingerprint

Hirsutism
Androgen Antagonists
Oral Contraceptives
Insulin
Placebos
Therapeutics
Progestins
Estrogens
Finasteride
Flutamide
Cyproterone Acetate
Network Meta-Analysis
Levonorgestrel
Spironolactone
MEDLINE
Randomized Controlled Trials
Confidence Intervals

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Biochemistry
  • Endocrinology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Treatment Options for Hirsutism : A Systematic Review and Network Meta-Analysis. / Barrionuevo, Patricia; Nabhan, Mohammed; Altayar, Osama; Wang, Zhen; Erwin, Patricia J.; Asi, Noor; Martin, Kathryn A.; Murad, Mohammad H.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 103, No. 4, 01.04.2018, p. 1258-1264.

Research output: Contribution to journalArticle

Barrionuevo, Patricia ; Nabhan, Mohammed ; Altayar, Osama ; Wang, Zhen ; Erwin, Patricia J. ; Asi, Noor ; Martin, Kathryn A. ; Murad, Mohammad H. / Treatment Options for Hirsutism : A Systematic Review and Network Meta-Analysis. In: Journal of Clinical Endocrinology and Metabolism. 2018 ; Vol. 103, No. 4. pp. 1258-1264.
@article{c9cffdeed5cb4135b93234bf6b747802,
title = "Treatment Options for Hirsutism: A Systematic Review and Network Meta-Analysis",
abstract = "Background Several pharmacologic treatments for hirsutism are used in practice; however, their relative efficacy is unclear. Methods We searched MEDLINE, EMBASE, and CENTRAL through January 2017 for randomized controlled trials (RCTs) with follow-up of at least 6 months that evaluated antiandrogens, insulin sensitizers, and oral contraceptives in women with hirsutism. Independent pairs of reviewers selected and appraised trials. Random-effects network meta-analysis was used to compare individual drugs and classes. Results We included 43 trials. Estrogen-progestin oral contraceptives pills (OCPs), antiandrogens, and insulin sensitizers were superior to placebo, with standardized mean reductions (95{\%} confidence intervals) of -0.94 (-1.49 to -0.38), -1.29 (-1.80 to -0.79), and -0.62 (-1.00 to -0.23), respectively. Antiandrogen monotherapy, the combination of OCP and antiandrogen, the combination of OCPs and insulin sensitizer, and the combination of antiandrogen and insulin sensitizer were superior to insulin sensitizer monotherapy. The combination of OCPs and antiandrogen was superior to OCPs. Antiandrogen monotherapy with flutamide, finasteride, and spironolactone were each superior to placebo but similar to each other in efficacy. OCPs containing levonorgestrel, cyproterone acetate, or drospirenone were similar in effectiveness to other OCPs or had trivial differences. The certainty in comparisons with placebo was moderate and for head-to-head comparisons was low. Conclusions Estrogen-progestin OCPs, antiandrogens, and insulin sensitizers are superior to placebo for the treatment of hirsutism.",
author = "Patricia Barrionuevo and Mohammed Nabhan and Osama Altayar and Zhen Wang and Erwin, {Patricia J.} and Noor Asi and Martin, {Kathryn A.} and Murad, {Mohammad H}",
year = "2018",
month = "4",
day = "1",
doi = "10.1210/jc.2017-02052",
language = "English (US)",
volume = "103",
pages = "1258--1264",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "4",

}

TY - JOUR

T1 - Treatment Options for Hirsutism

T2 - A Systematic Review and Network Meta-Analysis

AU - Barrionuevo, Patricia

AU - Nabhan, Mohammed

AU - Altayar, Osama

AU - Wang, Zhen

AU - Erwin, Patricia J.

AU - Asi, Noor

AU - Martin, Kathryn A.

AU - Murad, Mohammad H

PY - 2018/4/1

Y1 - 2018/4/1

N2 - Background Several pharmacologic treatments for hirsutism are used in practice; however, their relative efficacy is unclear. Methods We searched MEDLINE, EMBASE, and CENTRAL through January 2017 for randomized controlled trials (RCTs) with follow-up of at least 6 months that evaluated antiandrogens, insulin sensitizers, and oral contraceptives in women with hirsutism. Independent pairs of reviewers selected and appraised trials. Random-effects network meta-analysis was used to compare individual drugs and classes. Results We included 43 trials. Estrogen-progestin oral contraceptives pills (OCPs), antiandrogens, and insulin sensitizers were superior to placebo, with standardized mean reductions (95% confidence intervals) of -0.94 (-1.49 to -0.38), -1.29 (-1.80 to -0.79), and -0.62 (-1.00 to -0.23), respectively. Antiandrogen monotherapy, the combination of OCP and antiandrogen, the combination of OCPs and insulin sensitizer, and the combination of antiandrogen and insulin sensitizer were superior to insulin sensitizer monotherapy. The combination of OCPs and antiandrogen was superior to OCPs. Antiandrogen monotherapy with flutamide, finasteride, and spironolactone were each superior to placebo but similar to each other in efficacy. OCPs containing levonorgestrel, cyproterone acetate, or drospirenone were similar in effectiveness to other OCPs or had trivial differences. The certainty in comparisons with placebo was moderate and for head-to-head comparisons was low. Conclusions Estrogen-progestin OCPs, antiandrogens, and insulin sensitizers are superior to placebo for the treatment of hirsutism.

AB - Background Several pharmacologic treatments for hirsutism are used in practice; however, their relative efficacy is unclear. Methods We searched MEDLINE, EMBASE, and CENTRAL through January 2017 for randomized controlled trials (RCTs) with follow-up of at least 6 months that evaluated antiandrogens, insulin sensitizers, and oral contraceptives in women with hirsutism. Independent pairs of reviewers selected and appraised trials. Random-effects network meta-analysis was used to compare individual drugs and classes. Results We included 43 trials. Estrogen-progestin oral contraceptives pills (OCPs), antiandrogens, and insulin sensitizers were superior to placebo, with standardized mean reductions (95% confidence intervals) of -0.94 (-1.49 to -0.38), -1.29 (-1.80 to -0.79), and -0.62 (-1.00 to -0.23), respectively. Antiandrogen monotherapy, the combination of OCP and antiandrogen, the combination of OCPs and insulin sensitizer, and the combination of antiandrogen and insulin sensitizer were superior to insulin sensitizer monotherapy. The combination of OCPs and antiandrogen was superior to OCPs. Antiandrogen monotherapy with flutamide, finasteride, and spironolactone were each superior to placebo but similar to each other in efficacy. OCPs containing levonorgestrel, cyproterone acetate, or drospirenone were similar in effectiveness to other OCPs or had trivial differences. The certainty in comparisons with placebo was moderate and for head-to-head comparisons was low. Conclusions Estrogen-progestin OCPs, antiandrogens, and insulin sensitizers are superior to placebo for the treatment of hirsutism.

UR - http://www.scopus.com/inward/record.url?scp=85045474396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045474396&partnerID=8YFLogxK

U2 - 10.1210/jc.2017-02052

DO - 10.1210/jc.2017-02052

M3 - Article

C2 - 29522176

AN - SCOPUS:85045474396

VL - 103

SP - 1258

EP - 1264

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 4

ER -